Genomics Reporting Implementation Guide
1.1.0 - Ballot

This page is part of the Genetic Reporting Implementation Guide (v1.1.0: STU 2 Ballot 1) based on FHIR R4. The current version which supercedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions

: Example Task - PGxRecEx04 - XML Representation

Raw xml | Download



<Task xmlns="http://hl7.org/fhir">
  <id value="PGxRecEx04"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/task-rec-followup"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title="Codes: {http://loinc.org LA26422-8}">Decrease dose</span></p><p><b>description</b>: For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href="Patient-CGPatientExample01.html">Generated Summary: Medical Record Number: m123 (USUAL); Adam B. Everyman ; gender: male; birthDate: 1951-01-20</a></p><p><b>reasonReference</b>: <a href="Observation-TxImp04.html">Poor metabolizer. Generated Summary: <span title="Codes: {http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span>; <span title="Codes: {http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/TbdCodes therapeutic-implication}">Therapeutic Implication</span></a></p></div>
  </text>
  <status value="requested"/>
  <intent value="proposal"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA26422-8"/>
      <display value="Decrease dose"/>
    </coding>
  </code>
  <description
               value="For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations."/>
  <for>
    <reference value="Patient/CGPatientExample01"/>
  </for>
  <reasonReference>
    <reference value="Observation/TxImp04"/>
    <display value="Poor metabolizer"/>
  </reasonReference>
</Task>